Eflornithine placebo

DRUG2 trials

Sponsors

Cancer Prevention Pharmaceuticals, Inc., Vanderbilt-Ingram Cancer Center

Conditions

Familial Adenomatous PolyposisGastric CancerGastric Intestinal Metaplasia

Phase 2

Chemoprevention of Gastric Carcinogenesis

CompletedNCT02794428

Vanderbilt-Ingram Cancer CenterGastric Cancer, Gastric Intestinal Metaplasia

Start: 2016-09-19End: 2024-07-01Updated: 2024-10-16

Phase 3

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

CompletedNCT01483144

Cancer Prevention Pharmaceuticals, Inc.Familial Adenomatous Polyposis

Start: 2013-10-31End: 2019-03-31Updated: 2021-06-08

Related Papers

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-blinded, Randomized Clinical Trial.

2026-03-09

Abstract A016: Successful design and execution of two gastric cancer chemoprevention trials in Central America and Puerto Rico

Cancer Prevention Research2022-12-011 citations

Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial

Diseases of the Colon & Rectum2021-07-1517 citations

Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis

New England Journal of Medicine2020-09-0964 citations

Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.

2016-08-0232 citations